Mitral valve prolapse morphofunctional features by cardiovascular magnetic resonance: more than just a valvular disease

Angélica Romero Daza1*, Aalap Chokshi2, Patricia Pardo3, Nicolas Maneiro4, Ana Guijarro Contreras5,6, Jose M. Larrañaga-Moreira7,8, Borja Ibañez9,10,11, Valentin Fuster9,12, Leticia Fernández Friera9,11,13,14, Jorge Solís5,6 and Javier Sanz9,15*

Abstract

Introduction: Mitral valve (MV) prolapse (MVP) is a primary valvular abnormality. We hypothesized that additionally there are concomitant abnormalities of the left ventricle (LV) and MV apparatus in this entity even in the absence of significant mitral regurgitation (MR).

Objective: To characterize MV and LV anatomic and functional features in MVP with preserved LV ejection fraction, with and without significant MR, using cardiovascular magnetic resonance (CMR).

Methods: Consecutive MVP patients (n = 80, mean 52 years, 37% males) with preserved LV ejection fraction, and 44 controls (46 years, 52% males) by CMR were included, as well as 13 additional patients with “borderline” MVP. From cine images we quantified LV volumes, MV and LV anatomic measurements (including angle between diastolic and systolic annular planes, annular displacement, and basal inferolateral hypertrophy) and, using feature tracking, longitudinal and circumferential peak systolic strains.

Results: Significant MR was found in 46 (56%) MVP patients. Compared with controls, MVP patients had LV enlargement, basal inferolateral hypertrophy, higher posterior annular excursion, and reduced shortening of the papillary muscles. LV basal strains were significantly increased, particularly in several basal segments. These differences remained significant in patients without significant MR, and many persisted in “borderline” MVP.

Conclusions: In patients with MVP and preserved LV ejection fraction there is LV dilatation, basal inferolateral hypertrophy, exaggerated posterior annular displacement and increased basal deformation, even in the absence of significant MR or overt MVP. These findings suggest that MVP is a disease not only of the MV but also of the adjacent myocardium.

Keywords: Mitral valve prolapse, Cardiovascular magnetic resonance, Mitral regurgitation, Myocardial strain

Introduction

Mitral valve (MV) prolapse (MVP) is the most common cause of primary mitral regurgitation (MR) in developed countries [1]. MVP is defined as single or bileaflet prolapse, with or without leaflet thickening [2]. While MVP is primarily a disorder of the MV apparatus, few studies have suggested concomitant abnormalities in the left ventricle (LV). Increased LV diameters were described in...
the Framingham Study in association with MVP [3]. In addition, qualitatively abnormal LV motion patterns have been reported using angiocardiography [4] or cardiovascular magnetic resonance (CMR) [5], but quantitative measures of strain with echocardiography have yielded conflicting results [6, 7]. In addition, many of these studies did not account for the presence of significant MR as a possible mediator of observed abnormalities. In recent years CMR has emerged as an important technique for MVP characterization [2]. CMR is considered the non-invasive gold standard for LV evaluation and may allow better understanding of the interactions between the MV and LV. We hypothesized that LV morphological and functional abnormalities identified by CMR are part of the phenotypic expression of MVP even with preserved LV ejection fraction (LVEF) and in the absence of significant MR.

**Methods**

**Study population**

Patients with CMR-based diagnosis of MVP and preserved LVEF from 2 collaborating institutions were included: the CMR program at the Mount Sinai Hospital, New York City, New York, USA, and the Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain. Inclusion criteria were age ≥18 years, presence of MVP (defined as ≥2 mm displacement of one or both mitral leaflets into the left atrium [LA] during systole in the LV outflow tract long-axis view) [2], and LVEF ≥50% [8]. Exclusion criteria included: (1) conditions that could affect LV size/function and/or MV anatomy/geometry (dilated cardiomyopathy [LV dilation and systolic dysfunction in the absence of coronary artery disease or abnormal loading conditions proportionate to the degree of LV impairment [9]), prior infarct, prior mitral valve repair, additional moderate-to-severe valvular abnormalities [defined as any moderate or severe valvular stenosis or regurgitation with the exception of MR], or chest wall deformities such as pectus excavatum); (2) absence of phase contrast imaging or complete cine volumetric evaluation of the LV for quantification of MR severity; and (3) motion artifacts from respiratory motion and/or arrhythmia that precluded accurate measurements. Twenty-two patients fulfilling these characteristics were prospectively included at CNIC from October 2014 to March 2017. At Mount Sinai, a total of 151 consecutive patients with CMR based MVP diagnosis were retrospectively identified between March 2007 to January 2018. Of these, 93 were excluded (Fig. 1), resulting in 58 patients fulfilling inclusion criteria. Thus, a total of 80 patients were included. Patients were compared with a control group of 44 patients referred clinically for CMR at Mount Sinai Hospital, without evidence of structural heart disease (mild valvular regurgitation was allowed) or chest wall abnormality.

In order to evaluate the possible evolution of MVP, we additionally analyzed a separate group of patients (n = 13) with “borderline” MVP, whom we initially excluded. “Borderline” MVP was defined as morphology suggestive of prolapse but with leaflet displacement <2 mm into the LA (a phenotype that has been linked to future MVP) [10], illustrated in Additional file 1 and 2. Of these patients, phase contrast imaging was only available in 3 and late gadolinium enhancement (LGE) imaging in 11.

Baseline demographics, cardiovascular risk factors and electrocardiographic (ECG) findings were collected from patients’ electronic health records. The respective institutional review boards approved the study. Patients enrolled at CNIC provided written informed consent, while this requirement was waived at Mount Sinai.

**CMR imaging**

CMR studies were performed on 1.5 T (Magnetom Sonata or Magnetom Avanto, Siemens Healthineers, Erlangen, Germany, or Optima MR450w; General Electric Healthcare, Milwaukie, Wisconsin, USA) or 3 T (Ingenuity, Philips Healthcare, Best, The Netherlands) CMR units using dedicated phased-array surface coils as receivers. Sequences were acquired during end-expiratory breath holds with retrospective ECG or pulse gating. Balanced steady-state free-precession (bSSFP) cine...
images were acquired in three standard long-axis views (4-chamber, 2-chamber and LV outflow tract) in all patients. In addition, a stack of contiguous short-axis views covering the entire ventricles was available in all patients. Cine images were obtained with in-plane spatial resolution of ≤ 2 mm and temporal resolution ≤ 45 ms following current recommendations [11]. To determine the presence of significant MR, phase contrast velocity-encoded imaging was acquired orthogonal to the ascending aorta with typical velocity-encoding limit of 150 cm/s. In most patients, LGE imaging was obtained 10–15 min after the administration of 0.15–0.02 mmol/kg of gadolinium-based contrast agent.

**Image analysis**

Short-axis cine and phase contrast images were analyzed using specialized software (Argus, Siemens Healthineers; Extended MR WorkSpace, Philips Healthcare; or Qmass 6.0, Medis Medical Imaging Systems, Leiden, The Netherlands). All measurements of MV geometry in the LV outflow tract view and LV strain quantification were obtained with cvi<sup>42</sup> (version 5.6.3, Circle Cardiovascular Imaging, Calgary, Alberta, Canada), by the same observer.

LV mass, biventricular volumes and ejection fractions were quantified from bSSFP-cine images by manually tracing the endocardial and epicardial contours of the short axis at end-diastole and end-systole. Papillary muscles and trabeculations were considered part of the LV cavity [12]. In an LV outflow tract long-axis view we measured LV end-diastolic and end-systolic diameters as well as end-diastolic and end-systolic wall thickness of the basal inferolateral and mid inferolateral segments [13, 14] (Fig. 2). LA volume was derived by tracing end-systolic LA contours in the 4-chamber and 2-camer views and using the biplane area-length method [15]. Mitral regurgitant fraction (RF) was quantified comparing volumetric LV stroke volume to forward aortic flow in the aorta as previously described; significant MR was defined as RF > 15% [16]. The presence and location of LGE was determined visually.

Regarding MV anatomy and geometry, the following measurements were performed in the LV outflow tract long-axis view (Fig. 2):

- MVP distance: maximum displacement of the mitral leaflets beyond the annular plane during systole [2].
- Mitral annular diameters: measured from the aorto-mitral junction to the posterior mitral leaflet insertion point both in diastole and systole, with their difference defined as annular lengthening.
- Maximum leaflet thickness, measured in diastole.
- Length of the posteromedial papillary muscle (PM): measured in end-diastole and end-systole, with their difference defined as PM shortening.
- Distance of the tip of the posteromedial PM to the tip of the posterior mitral leaflet as a surrogate of “chordal length”, measured in end-diastole and end-systole.
- Distances from the posteromedial PM insertion point to the anterior and posterior mitral annulus. These were also measured in end-diastole and end-systole, as well as their difference.
- Distances from the anterior and posterior mitral annulus to external reference point (the point of muscle-fat interface in the chest wall on a line traversing the center of the annular plane and LV apex) were measured in end-diastole and end-systole, as well as their difference.
- Mitral annular disjunction (MAD): distance from the LA wall-mitral posterior leaflet junction to the LA wall-LV inferolateral wall junction [17], measured during diastole and systole.
- Mitral annulus angle: measured as the angle between the mitral annular planes at end-diastole and end-systole.

We quantified LV peak systolic longitudinal and circumferential strains using cvi<sup>42</sup> feature-tracking module. Epicardial and endocardial borders, excluding the papillary muscles, were manually drawn in the end-diastolic phase in the short axis, 4-chamber, 2-chamber and LV outflow tract long-axis views, and then automatically propagated through the cardiac cycle (Fig. 3).

---

**Fig. 2** Cardiovascular magnetic resonance (CMR) balanced steady state free precession -cine left ventricular outflow tract long-axis view in a patient with posterior mitral valve prolapse. (A and C) End-diastole phase showing measurements of the mitral annulus diameter (ADD), left ventricle end-diastotic diameter (LVEDD), posteroomedial papillary muscle length (PMMLD), chord length from papillary muscle to the tip of the leaflet (CLD), distance from PM insertion point to the anterior and posterior mitral annulus (PMAAD and PMPAD), basal and mid inferolateral wall thickness (BWTS and MWTS), anterior and posterior leaflet thickness (AT and PT). (B–D) End-systole phase showing measurements of the mitral annulus diameter (ADS), maximum MVP (circle), left ventricle end-systolic diameter (LVESD), basal and mid inferolateral wall thickness (BWTS and MWTS), posteroomedial papillary muscle length (PMMLS), mitral annular disjunction (star), distance from PML insertion point to the anterior mitral annulus and to the posterior mitral annulus (PMAAS and PMPAS). Finally, end-diastole (E) and end-systole (F) phase showing the mitral annulus diameter (dotted line), and distance from the anterior (AARP) and posterior (PARP) mitral annulus to the external reference point (red dot indicates the muscle-fat interface in the chest wall).
Fig. 2 (See legend on previous page.)
Strains were obtained following the standard 16-segment model [18], and then averaged for the basal, mid, and apical levels as well for the entire LV.

**Statistical analysis**
Categorical data are expressed as number (percentage) whereas continuous variables are presented as median [interquartile range], since most were not normally distributed according to the Shapiro–Wilk test. For comparisons between MVP patients and controls, differences for categorical variables were evaluated by the chi-square ($\chi^2$) or Fisher exact tests, and non-parametric tests such as Wilcoxon rank-sum for continuous variables as appropriate. To ensure that potential LV abnormalities were not secondary to volume overload in the presence of MR, a sub-analysis was performed comparing controls with MVP patients without significant MR. Similar comparisons were performed between controls and patients with “borderline” MVP.

Reproducibility of MV geometry and LV systolic strain measurements was assessed in 20 randomly selected patients, including 10 with MVP and 10 controls. Intra-observer variability was obtained from repeated measurements performed by the same reader at least one month apart, and interobserver variability by a second independent reader. Variability was evaluated using the intraclass correlation coefficient (ICC). The following levels of agreement were used: excellent for ICC > 0.74, good for ICC 0.6–0.74, fair for ICC 0.4–0.59, poor for ICC < 0.4 [19].

In all cases, a $p$ value < 0.05 was considered statistically significant. The Holm-Bonferroni correction [20] was used to account for multiple testing in comparisons of segmental myocardial strain. All statistical analyses were performed with STATA (version 13.1, Stata Corporation, College Station, Texas, USA).

**Results**

**Patient characteristics**
The clinical characteristics of the MVP (including MVP without significant MR), control and “borderline” MVP groups are summarized in Table 1. Controls were slightly younger than the overall MVP group, and had higher body surface area and prevalence of obesity groups. Other than these measures, there were no differences regarding and sex, remaining cardiovascular risk factors or symptoms between these 2 groups.

**Standard CMR measurements**
In the MVP cohort 46 patients had significant (at least moderate) MR by CMR. By design, no patients in the control group had significant MR. CMR measurements
Table 1  Patient characteristics

|                      | Controls (n = 44) | MVP (all) (n = 80) | MVP (No significant MR) (n = 34) | "Borderline" (n = 13) |
|----------------------|------------------|-------------------|----------------------------------|----------------------|
| Age (y)              | 46 [38–57]       | 52 [40–63]*       | 50 [35–59]                       | 51 [36–63]           |
| Male                 | 23 (52%)         | 37 (46%)          | 14 (41%)                         | 7 (50%)              |
| BSA (m²)             | 1.9 [1.7–2.1]    | 1.7 [1.6–2.0]*    | 1.7 [1.6–2.0]*                   | 1.8 [1.6–1.9]*       |
| Hypertension         | 18/42 (43%)      | 27/73 (37%)       | 10/31 (32%)                      | 1/9 (11%)            |
| Diabetes mellitus    | 5/42 (12%)       | 0/51 (0%)         | 0/23 (0%)                        | 1/13 (13%)           |
| Current or former smoker | 13/42 (31%)  | 13/50 (26%)       | 6/23 (26%)                       | 0/9 (0%)*            |
| Dyslipidemia         | 12/42 (29%)      | 16/52 (31%)       | 7/23 (30%)                       | 2/9 (22%)            |
| Obesity              | 10/42 (23%)      | 6/80 (8%)**       | 3/34 (9%)*                       | 0/13 (0%)*           |
| Family history of MVP (%) | 0/41 (0%)  | 5/73 (7%)         | 2/31 (6%)                        | 0/9 (0%)             |
| Dyspnea              | 12/41 (29%)      | 19/71 (27%)       | 7/31 (23%)                       | 2/8 (25%)            |
| Chest pain           | 9/41 (22%)       | 17/72 (24%)       | 7/32 (22%)                       | 1/8 (13%)            |
| Palpitations         | 17/41 (41%)      | 50/98 (51%)       | 18/31 (58%)                      | 4/8 (50%)            |
| Sinus rhythm         | 44/44 (100%)     | 78/78 (100%)      | 34/34 (100%)                     | 13/13 (100%)         |

BSA: body surface area. MR: mitral regurgitation. MVP: mitral valve prolapse.

*P Value < 0.05 versus controls. **P Value < 0.01 versus controls.

Table 2  CMR chamber quantification

|                      | Controls [n = 44] | MVP (all) [n = 80] | MVP (No significant MR) [n = 34] | "Borderline" MVP [n = 13] |
|----------------------|------------------|-------------------|----------------------------------|----------------------|
| LVEDV (ml/m²)        | 73 [67–90]       | 98 [86–116]**     | 90 [85–101]**                    | 83 [74–89]           |
| LVESV (ml/m²)        | 30 [25–34]       | 39 [31–44]**      | 37 [30–44]*                      | 35 [32–37]           |
| LVEF (%)             | 61 [57–65]       | 60 [57–66]        | 60 [57–64]                       | 59 [56–62]           |
| LV mass (g/m²)       | 51 [42–59]       | 54 [46–65]        | 48 [43–59]                       | 47 [41–54]           |
| LV end-diastolic diameter (cm²/m²) | 2.6 [2.3–2.8]     | 2.8 [2.5–3.2]**   | 2.7 [2.5–3.2]*                   | 2.8 [2.5–2.9]*       |
| LV end-systolic diameter (cm²/m²) | 1.7 [1.5–2.0]     | 1.9 [1.7–2.2]*    | 1.9 [1.8–2.1]*                   | 1.9 [1.8–2.1]        |
| Basal inferolateral thickness in diastole (cm) | 0.7 [0.6–0.9]     | 0.8 [0.7–1.0]*    | 0.7 [0.6–0.9]                     | 0.7 [0.6–0.7]        |
| Basal inferolateral thickness in systole (cm) | 1.2 [1.1–1.4]     | 1.5 [1.3–1.7]**   | 1.5 [1.3–1.6]**                  | 1.3 [1.2–1.4]        |
| Mid inferolateral thickness in diastole (cm) | 0.6 [0.5–0.8]     | 0.6 [0.5–0.7]     | 0.6 [0.4–0.7]*                   | 0.4 [0.3–0.5]**      |
| Mid inferolateral thickness in systole (cm) | 1 [0.9–1.2]       | 1 [0.8–1.2]       | 1 [0.7–1.2]                      | 0.7 [0.6–0.8]**      |
| Basal-to-mid inferolateral end-diastolic thickness ratio | 1.1 [1–1.3]       | 1.4 [1.1–1.7]**   | 1.4 [1–1.6]*                     | 1.7 [1.3–1.7]**      |
| Basal-to-mid inferolateral end-systolic thickness ratio | 1.2 [1–1.4]       | 1.5 [1.2–1.7]**   | 1.6 [1.3–1.8]**                  | 1.9 [1.8–2.0]**      |
| RVEDV (ml/m²)        | 76 [69–86]       | 85 [75–104]*      | 85 [81–101]*                     | 74 [63–99]           |
| RVESV (ml/m²)        | 33 [28–38]       | 36 [28–47]        | 37 [28–48]                       | 37 [27–42]           |
| RVEF (%)             | 57 [55–62]       | 59 [53–65]        | 59 [53–63]                       | 56 [51–60]           |
| LA volume (ml/m²)    | 38 [30–43]       | 50 [40–67]**      | 41 [34–49]                       | 50 [36–59]*          |
| Mitral valve regurgitant fraction (%) | 4 [0–6]         | 20 [11–32]*       | 9 [1–13]                         | N/A                  |
| LGE performed        | 44 (100%)        | 70 (85%)          | 25 (74%)                         | 11 (85%)             |
| Myocardial LGE       | 2 (5%)           | 23 (33%)**        | 8 (32%)*                         | 3 (27%)              |
| Intramyocardial pattern | 2 (5%)        | 16 (23%)*         | 4 (16%)*                         | 3 (27%)              |
| Inferolateral LGE    | 0 (0%)           | 22 (32%)*         | 8 (33%)*                         | 2 (18%)              |

Values expressed as n (%) or medians [interquartile range].

LA: left atrium. LGE: late gadolinium enhancement. LV: left ventricle. LVEDV: left ventricle end-diastolic volume. LVEF: left ventricle ejection fraction. LVESV: left ventricle end-systolic volume. SAX: short axis view.

*P Value < 0.05 versus controls. **P Value < 0.01 versus controls.
of cardiac chambers are summarized in Table 2. Patients with MVP, including those without significant MR, showed increased LV end-systolic and end-diastolic dimensions without significant differences in LV mass or LVEF. RV end-diastolic volume was also higher in MVP patients regardless of MR, whereas LA volumes were increased only in the overall group but not in the cohort without significant MR. LV end-diastolic basal inferolateral wall thickness was increased in patients with MVP and significant MR, and mid inferolateral wall thickness reduced in in the cohort without significant MR. However, basal inferolateral wall thickness was increased in LV end-systole and mid inferolateral wall thickness reduced in end-diastole regardless of the presence of MR, leading to increased basal-to-mid inferolateral wall thickness ratios (Table 2).

Myocardial LGE was available in 44 controls, 70 MVP patients, and 11 patients with “borderline MVP”. There were two control subjects with focal LGE in the inferior RV insertion point, considered nonspecific. Regarding MVP patients, 23 (33%) had myocardial LGE, being intramyocardial the most common pattern and the inferolateral segment the most commonly affected (Table 2). Examples of abnormal LGE are shown in Additional files 3.

**MV apparatus geometry**

MV apparatus measurements are presented in Table 3. In patients with MVP, isolated posterior leaflet involvement was the most common type (n = 45; 56%), followed by bileaflet MVP (n = 32; 40%) and isolated anterior leaflet MVP (n = 1; 1%). The median MVP distance was 0.7 cm. As expected [2], leaflet thickness and mitral annular diameters were increased in MVP. Mitral annular disjunction (MAD) was present in 42% of MVP patients versus only one (2%) patient in the control group. In addition, the MV annulus angle was increased in MVP patients regardless of MR, indicating increased excursion of the posterior annulus with respect to the mitroaortic junction. This was confirmed by increased shortening in the distance from the posterior mitral annulus to the external reference point, also in the absence of significant MR (see Table 3), a difference that was not noted for the anterior annulus.

The end-diastolic distance PM to both anterior and posterior mitral annulus was longer in MVP patients even in the absence of significant MR. However, there were no significant end-systolic differences, leading to increased shortening in the PM-annulus distances in MVP. Conversely, PM length was preserved in end-diastole but increased in end-systole in MVP patients, resulting in reduced PM shortening. Systolic distance between the tip of the PM and the posterior mitral leaflet (“chordal length”) was increased in the overall MVP group but not in those without significant MR, with no systolic differences in either group.

**LV myocardial strain**

Global strain values, as well as those segmental strains showing significant differences between controls and MVP patients (including those without significant MR) are shown in Table 4. There were no differences in the global longitudinal strain or global circumferential strain measurements; however, the MVP group had increased basal longitudinal strain values regardless of the presence of MR, and increased basal circumferential strain in the overall cohort. When evaluating segmental strains, differences were significant in the overall cohort for longitudinal strain in the basal anteroseptal, anterior, anterolateral, and inferolateral segments, in the overall cohort for circumferential strain in the basal anterior and anterolateral segments, and in the group without MR for circumferential strain in the basal anterolateral segment. (Table 4, Fig. 4).

There were no other consistent significant differences regarding segmental peak systolic strains (see Fig. 4, and Additional files 4 and 5).

In simple linear regression analysis, there was not significant correlation between global or segmental longitudinal peak systolic strain and MVP severity (p > 0.05, for all segments). Regarding MV leaflets thickness; there was an increase of -13% and -15% in peak systolic longitudinal strain in basal segments per every increase of 1 mm in mitral valve anterior and posterior leaflet thickness, respectively (p < 0.05).

We also compared strain values between those with isolated posterior versus bileaflet MVP to evaluate if there were differences in myocardial deformation between these 2 groups. As demonstrated in Additional file 6, we did not find any significant differences.

**Patients with “borderline” MVP**

Patients with “borderline” MVP shared some of the differences of MVP patients in comparison with controls (Tables 1, 2, 3 and 4). Regarding clinical characteristics, they also had lower body surface area and less obesity. On cine imaging they displayed some degree of LV and LA enlargement, increases in LV end-diastolic and end-systolic basal-to-mid inferolateral thickness ratio, and higher prevalence of LGE than controls (although the latter not-statistically significance probably due to small numbers) with a pattern and distribution that resembled that of MVP. Regarding MV anatomy and geometry, patients with “borderline” MVP also demonstrated thicker leaflets, larger annular diameters, more frequent
MAD, increased distance from the posterior and anterior annulus to external reference point as well as increased shortening in the case of the posterior annulus, increased diastolic distance of the anterior annulus to the PM, larger systolic PM length, and increased distance from the PM tip to the posterior leaflet tip ("chordal length"). In addition, they demonstrated increased longitudinal strains in the basal anterolateral segment, and increased circumferential strain in the base when considered globally.

Interobsever and intraobserver reproducibility
In both inter- and intra-observer analyses, the reproducibility of strain and MV measurements was good to excellent on average. For longitudinal peak systolic strain
measurements, the median inter-observer ICC was 0.74 [0.56–0.85] and intra-observer ICC was 0.74 [0.56–0.79]. Regarding circumferential peak systolic strain, the corresponding ICCs were 0.83 [0.72–0.90] and 0.77 [0.66–0.85], respectively. Finally, of MV measurements demonstrated median inter-observer ICC of 0.79 [0.64–0.94] and intra-observer ICC of 0.77 [0.66–0.88].

Table 4  Left ventricle peak systolic longitudinal and circumferential strain

| LV peak systolic longitudinal strain (%) | Controls [n = 44] | MVP (all) [n = 78] | MVP (no significant MR) [n = 34] | “Borderline” MVP [n = 13] |
|----------------------------------------|------------------|-------------------|-----------------------------|------------------------|
| Global                                 | −13.9 [−15.5−11.6] | −14.8 [−16.9−13.1] | −14.3 [−16.0−13.1]          | −15 [−16.6−13.5]      |
| Basal                                  | −10.4 [−12.7−8.5]  | −13.7 [−17.5−11.3]** | −12.9 [−16.2−9.5]*          | −13.5 [−14.8−11.9]**  |
| Basal anterior                         | −13.5 [−16.3−10.6] | −18.2 [−20.5−14.6]** | −16.5 [−19.5−10.8]          | −15.1 [−17.9−13.5]    |
| Basal anterolateral                    | −11.5 [−14.9−8.0]  | −17.4 [−20.9−11.7]** | −16.5 [−21.0−9.4]           | −15.9 [−17.4−12.2]**  |
| Basal inferolateral                    | −10.9 [−13.4−9.1]  | −14.5 [−18.1−11.8]** | −13.2 [−17.2−11.7]          | −13.7 [−18.2−8.9]     |
| Basal anteroseptal                     | −9.8 [−11.8−5.2]   | −12.7 [−15.5−8.8]**  | −11.4 [−15.1−7.3]           | −9.9 [−14.4−9.2]      |

| LV peak systolic circumferential (strain %) | Controls (n = 43) | MVP (all) [n = 78] | MVP (no significant MR) [n = 34] | “Borderline” MVP [n = 13] |
|---------------------------------------------|------------------|-------------------|-----------------------------|------------------------|
| Global                                      | −16.4 [−17.6−13.8] | −16.23 [−18.5−14.8] | −15.8 [−17.1−14.8]          | −16.6 [−17.3−14.7]    |
| Basal                                       | −14.6 [−16.1−12.1] | −16.2 [−17.6−14.1]** | −15.3 [−16.8−14.2]          | −16.6 [−18.1−14.7]**  |
| Basal anterior                              | −18.3 [−19.6−15.0] | −20.1 [−22.4−17.8]** | −19.6 [−22.4−17.6]          | −17.9 [−20−16.3]      |
| Basal anterolateral                         | −16.6 [−19.6−13.4] | −19.8 [−21.9−17.4]** | −19.9 [−22.5−17.6]**        | −18.9 [−22.1−17.4]    |

Values expressed as medians (interquartile range). *P Value < 0.05 versus controls. **P Value < 0.01 versus controls. *P Value < 0.05 versus controls after Holm-Bonferroni correction. LV left ventricle, MR mitral regurgitation; MVP mitral valve prolapse. Other regional strains are shown in the Additional files 4 and 5.

Fig. 4  Circumferential and longitudinal peak systolic strain analysis, representing the differences between MVP (A) and controls (B). Bull’s-Eye figures representing American Heart Association LV segmentation, with longitudinal and circumferential peak systolic strain. Values are shown for MVP cases (C) and controls (D). LV Left ventricle. MVP Mitral valve prolapse. *P Value < 0.05 versus controls.
Discussion

MVP is considered a primary disorder of the MV, with thickening and hypermobility of the leaflets. Although the importance of leaflet abnormalities cannot be downplayed, our findings suggest MVP is also associated with abnormalities and hypermobility of the annulus and adjacent myocardium (Fig. 5). This is supported by (1) increased ventricular dimensions; (2) abnormal myocardial phenotype with basal inferolateral hypertrophy, mid inferolateral thinning, and thus higher basal-to-mid inferolateral wall thickness ratio; (3) increased LV basal strains, particularly of the anterior, anterolateral and inferolateral segments; (4) increased posterior annular excursion (as reflected by a higher mitral annulus angle and bulging of the basal inferolateral segment, respectively. The black double arrow dotted line indicates the PM to anterior annulus distance. The mitral plane both in end diastole and end-systole is indicated by the red arrow. These two planes have been superimposed in the insert illustrating the mitral annulus angle (in blue) as the angle between the two. LV: left ventricle. PM: papillary muscle); and (5) presence of MAD. Importantly, these differences were significant regardless of the presence of significant MR (and cannot be attributed to LV volume overload) and many were observed in patients with borderline MVP, suggesting that they are not secondary to full-blown leaflet prolapse.

In the Framingham Heart Study [3], 83 participants with MVP had larger LV and LA echocardiographic size than age- and sex-matched controls, although presence or severity of MR were not accounted for. Similar findings were reported more recently in 101 MVP patients evaluated with CMR [6]. In a smaller (n = 20) echocardiographic study [21], patients with MVP also had increased LV dimensions even in the absence of MR. In the present study of 80 patients with MVP as the only significant cardiac abnormality and 44 controls without structural heart disease, we also found higher LV volumes regardless of MR presence, although the LA was enlarged only in the presence of significant MR. Interestingly, a similar phenotype of a (typically mild) dilated cardiomyopathy has been observed in Marfan patients, who not uncommonly also present with MVP [22]. In addition, we noted increases in RV volumes in the MVP population even without significant MR which, to the best of our knowledge, has not been described before. Although the reasons for this are unclear, these findings may support our hypothesis that MVP represents a combination of abnormalities of not only the mitral apparatus but also cardiac chambers.

Hypertrophy confined to the basal inferolateral LV wall was initially described with echocardiography and thought to represent increased LV mass or, subsequently, a form of hypertrophic cardiomyopathy [23]. More recently and using CMR in 63 MVP patients and 20 controls, Zia et al. described LV basal hypertrophy and increased basal-to-mid thickness ratio in all LV walls, particularly anterolateral and inferolateral [14]. The severity of basal inferolateral hypertrophy correlated with the degree of annular excursion (similar to the correlation we found with MV annular angle), so focal hypertrophy was hypothesized to be adaptive to increased regional myocardial function. In our patients we also noted localized basal inferolateral hypertrophy, which, together
with mid inferolateral thinning, led to increased basal-to-mid inferolateral thickness ratio. While these differences were more evident in systole, in favor of increased contractile function of the basal inferolateral segment, we also observed reduced end-diastolic thickness of the mid inferolateral segment, which suggests that phenotypic myocardial abnormalities in MVP extend beyond the perivalvular myocardium. In agreement with others [24, 25], we also observed the presence of LGE in MVP, particularly with a non-ischemic distribution and in the basal inferolateral segments, and a finding that has been linked to ventricular arrhythmias. The reasons for this are unclear but may be related to hypercontractility in this region, increased mechanical stress and, eventually localized hypertrophy.

The differences in regional LV function were confirmed by consistent increases in longitudinal and/or circumferential peak systolic strain in the basal anterior, anterolateral and inferolateral segments, and reductions in deformation in the mid inferior segment regardless of the presence of significant MR. However, we did not find differences in global strains, as opposed to other series of patients with predominantly moderate to severe MR [6, 26]. To the best of our knowledge, our study is the first study to characterize regional LV deformation in MVP patients with and without significant MR using CMR. Several studies using speckle-tracking echocardiography for evaluation of regional strain in MVP have yielded conflicting results. Fukuda et al. [27] reported reduced basal strains in association with annular dilatation in a cohort of 130 MVP patients, although they tended to have significant MR and LV dilatation. In patients with MVP and preserved LVEF, Zito et al. noted increased global circumferential strain and LV twist in the presence of moderate MR, with trends for reductions when MR was severe [28]. Lee et al. [6] found no differences in basal circumferential strain in MVP with preserved LVEF when compared to controls. Similarly, no differences in peak global or segmental longitudinal strain were noted in another study of MVP patients also with preserved LVEF, although global strain rates were increased [29].

SanFilippo et al. [30] and later Lee et al. [31] described increased shortening of the PM tip-annulus distance related to decreases only in systole. Because the annular plane did not demonstrate increased excursion with respect to an external reference point, the authors concluded that this was due to traction of the PM towards the MV rather than annular hypermobility towards the apex. Indeed, we found elongation of the PM in systole likely related to increased traction, as well reduced PM longitudinal shortening. However, we also noted as well as increased diastolic PM-annular distance, which was seen consistently and regardless of MR presence. Thus, in our study, the increased shortening of the PM-annulus distance during the cardiac cycle was due to diastolic increases rather than reductions in systole, as also noted by others [32]. As mitral chordae may be elongated in MVP, we measured the distance of the tip of the posteromedial PM to the tip of the posterior leaflet. We indeed found an increase in this distance during systole, suggesting that increased traction and mechanical stress during this period, with no differences during diastole where the chordae would not be fully stretched. Therefore, chordal elongation would not explain the increased distance from the PM base to the mitral annuls that we observed only in diastole. The augmented basal lateral strain discussed above was accompanied by increased longitudinal excursion of the posterior annulus (Fig. 2). In the normal MV the posterior annulus has larger longitudinal translation than the anterior annulus, which is tethered to the aortic root [33], but this difference is significantly accentuated in MVP. These findings support a component of relative hypermobility of the posterior annulus portion with “traction” of the PM from the more “fixed” anterior annulus. The differences between the study by SanFilippo and ours may be explained by different reasons. First, they measured the distance from the tip of the PM rather than its insertion as we did; thus, the influence of PM elongation or shortening was not accounted for. Second, the distance was measured to the center of the annular plane, which would prevent identifying differential behavior of its anterior and posterior components. Third, their study included 13 MVP patients and 18 controls studied with 2D echocardiography, whereas we enrolled 80 MVP patients and 44 controls evaluated with CMR.

A dissociation of annular and LV contraction suggesting ventricular annular decoupling has been described in MVP and related to MAD [6, 34] which in turn has been associated with more severe MVP [6], basal inferolateral abnormal motion (“curling”), regional hypertrophy [5] and MR [35]. The concept of MAD was introduced by Bharati et al. [36] in 1981, with subsequent pathology studies confirming this abnormality both in hearts with and without MVP [17]. The authors of the latter study hypothesized that MAD enables systolic annular expansion leading to changes in posterior leaflet geometry that favor prolapse and eventually secondary leaflet thickening. Our findings are consistent with this hypothesis. In fact, visually it often appears that MVP is actually consequence of excessive apical annular displacement rather than atrial leaflet displacement (Fig. 6 and Additional file 7). We hypothesize that annular and basal LV hypermobility (particularly of the posterior components) may be a primary component of the MVP complex, as opposed to secondary to leaflet prolapse. Posterior hypermobility is supported by increased LV basal
strains, of mitral annulus angles and of the shortening of the distance from the annulus to an external reference point, even in the absence of frank MVP (or significant MR). This may reflect LV-annular decoupling (which can manifest anatomically as MAD) and reduced “anchorage” of the LV basal myocardium to the MV annulus. This disruption of the “ventriculo-mitral unit” may lead to excessive systolic LV motion [5] towards the apex, insufficiently opposed by the mitral closing forces in the opposite direction and, eventually, PM elongation, increases in the diastolic PM-annulus distance, and compensatory regional hypertrophy. These findings may partly explain why annular stabilization through prosthetic annuloplasty or other techniques is an important component in the MVP surgical repair [37].

Study limitations
Although the patients were recruited prospectively in CNIC, those at Mount Sinai were identified retrospectively, so not all clinical data were available in every patient, and some degree of referral bias is to be expected. Because of the design of the study, LGE imaging was not available in all patients. In addition, the presence of interstitial fibrosis with T1 mapping has been reported in MVP [38] and associated as well with ventricular arrhythmias [38, 39], but could not be studied in our cohort because most patients were scanned before this option was available for clinical use at Mount Sinai. Nonetheless, the role of replacement and interstitial fibrosis in MVP is beyond the scope of this work. When measuring MV geometry/anaomy and strain, the observer was blinded to the quantitative analysis of LV volumes or aortic flow. However, blinding to the presence of MVP was not possible since this can be detected in the cine images employed for the analyses. We observed mild RV dilatation in MVP. Because patients with known or CMR-based significant valvular abnormality other than MR were excluded, and echocardiographic data that was available in 67% of controls and 54% of MVP patients demonstrated right ventricular systolic pressures of 28 [21–31] mmHg and 26 [19–30] mmHg, respectively (data not shown), we speculate that tricuspid regurgitation or pulmonary hypertension do not explain these findings. However, this possibility was not tested formally and cannot be completely excluded. While the findings in patients with “borderline” MVP suggest that LV morphological and functional abnormalities may precede, and thus are not secondary to, full leaflet prolapse, this was a cross-sectional study, longitudinal follow up is needed to confirm these observations and given the small number of patients, findings in this subgroup should be considered exploratory and hypothesis-generating. CMR cannot replace the easy applicability of the echo as bedside examination; however, the higher resolution of the CMR images combined with the multiplanar dynamic series can be an excellent “basic science” tool in this delicate and fundamental chapter of cardiac mechanics.
Conclusions
MVP is a complex entity, with abnormalities not limited to the valve apparatus, but of the whole “ventricle-mitral unit”. Morphological and functional abnormalities of the posterior annulus and adjacent basal myocardium (basal inferolateral hypertrophy, mid inferolateral thinning, MAD, hypermobility, increased strain) appear to be a central component of MVP and may have a role in its pathogenesis.

Abbreviations
BSA: Body surface area; bSSFP: Balanced steady state free precession; CMR: Cardiovascular magnetic resonance; ECG: Electrocardiogram; ICC: Intraclass correlation coefficient; LA: Left atrium/left atrial; LGE: Late gadolinium enhancement; LV: Left ventricle/left ventricular; LVEDD: Left ventricular end-diastolic dimension; LVEDV: Left ventricular end-diastolic volume; LVEF: Left ventricle ejection fraction; LVESV: Left ventricular end-systolic volume; MAD: Mitral annular disjunction; MR: Mitral regurgitation; MV: Mitral valve; MVP: Mitral valve prolapse; PM: Papillary muscle; RF: Regurgitant fraction; RV: Right ventricle/right ventricular; RVEDD: Right ventricular end-diastolic volume; RVEDV: Right ventricular end-diastolic volume; RVEF: Right ventricular ejection fraction; RVESV: Right ventricular end-systolic volume.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12968-021-00800-w.

Additional file 1. Borderline mitral valve prolapse. Movies showing examples of patients with mitral leaflet morphology suggestive of prolapse but posterior displacement into the left atrium <2 mm.

Additional file 2. Borderline mitral valve prolapse. Movies showing examples of patients with mitral leaflet morphology suggestive of prolapse but posterior displacement into the left atrium <2 mm.

Additional file 3. Late gadolinium enhancement in patients with mitral valve prolapse. Examples of 4 patients with MVP and typical examples of intramyocardial LGE (asterisks) in the basal inferolateral (A and B), basal inferior (C) and basal anterolateral (D) segments. An example of papillary muscle LGE is also shown in C (arrow).

Additional file 4. Left ventricle peak systolic longitudinal strain. Table including individual LV segments peak systolic longitudinal strain measurements.

Additional file 5. Left ventricle peak systolic circumferential strain. Table including individual LV segments peak systolic circumferential strain measurements.

Additional file 6. Geometric and myocardial strain comparison between mitral valve prolapse patients with phase contrast in the ascending aorta and controls. Table showing the comparison between controls, MVP patients, and MVP without significant MR corroborated by phase contrast.

Additional file 7. Excessive apical annular displacement in MVP. Movie showing excessive apical annular displacement (rather than atrial leaflet displacement) in a patient with MVP.

Acknowledgements
Not applicable.

Authors’ contributions
ARD drafted the manuscript and performed data collection and analyses. AC, PP, NM, AGC, and JML-M performed data collection and analyses. BI and VF provided funding for the CNIC study portion and performed a critical review of the manuscript. LFF and JS designed the study, recruited patients at CNIC and performed a critical review of the manuscript. JS designed the study and performed a critical review of the manuscript. All authors read and approved the final manuscript.

Funding
Dr. Angelica Romero Daza has received research and educational grant from the Sociedad Española de Cardiología, Madrid, Spain. The CNIC is supported by the Ministerio de Ciencia, Innovación y Universidades, and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Patients from CNIC provided written informed consent and the protocol was approved by the Ethics Committee of Hospital Carlos III (internal code P2/12). The requirement for informed consent was waived at Mount Sinai and the protocol was approved by the Institutional Review Board (#17-1365).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Hospital La Luz-QuironSalud, Maestro Ángel Llorca, 8, 28003 Madrid, Spain. 2Englewood Hospital and Medical Center, Englewood, NJ, USA. 3Department of Cardiology, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain. 4Hospital Universitario 12 de Octubre, Madrid, Spain. 5Unidad de Gestión Clínica del Corazón, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain. 6Centro de Investigación Biomédica en Enfermedades Cardiovasculares, Instituto Biotecnológico de Málaga, Málaga, Spain. 7Inherited Cardiovascular Diseases Unit, Cardiology Service, Complejo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde (SERGAS), A Coruña, Spain. 8Instituto de Investigación Biomédica de A Coruña (INIBIC), Universidad da Coruña, A Coruña, Spain. 9Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain. 10IS-Fundación Jiménez Díaz Hospital, Madrid, Spain. 11CIBERCV, Madrid, Spain. 12Icahn School of Medicine at Mount Sinai, Zena and Michael A. Wiener Cardiovascular Institute, New York, NY, USA. 13Hospital Universitario HM Montepríncipe- CIEC, Madrid, Spain. 14Universidad CEU San Pablo, Madrid, Spain. 15Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, P.O. Box 1030, New York, NY 10029, USA.

Received: 8 December 2020 Accepted: 30 July 2021
Published online: 11 October 2021

References
1. Freed LA, Levy D, Levine RA, Larson MG, Evans JC, Fuller DL, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med. 1999;341(1):1–7.
2. Han Y, Peters DC, Salton CJ, Bzymek D, Nezafat R, Goodf B, et al. Cardiovascular magnetic resonance characterization of mitral valve prolapse. JACC Cardiovasc Imaging. 2008;1(3):294–303.
3. Freed LA, Benjamin EJ, Leviy D, Larson MG, Evans JC, Fuller DL, et al. Mitral valve prolapse in the general population: the benign nature of echocardiographic features in the Framingham Heart Study. J Am Coll Cardiol. 2002;40(7):1298–304.
4. Scampordin G, Yang SS, Manarho V, Goldberg H, Gooch AS. Left ventricular abnormalities in prolapsed mitral leaflet syndrome Review of eighty-seven cases. Circulation. 1973;48(2):287–97.
5. Marra MP, Basso C, De Lazzari M, Rizzo S, Capriani A, Giorgi B, et al. Morphofunctional abnormalities of mitral annulus and arrhythmic mitral valve prolapse. Circ Cardiovasc Imaging. 2016. https://doi.org/10.1161/CIRCIMAGING.116.005030.
6. Lee AP-W, Jin C-N, Fan Y, Wong RHL, Underwood MJ, Wan S. Functional implication of mitral annular disjunction in mitral valve prolapse. JACC Cardiovascular Imaging. 2017;10(12):1424–33.

7. Fukuda S, Song JK, Mahara K, Kuwaki H, Jang JY, Takeuchi M, et al. Basal left ventricular dilatation and reduced contraction in patients with mitral valve prolapse can be secondary to annular dilatation. Circ Cardiovasc Imaging. 2016. doi:https://10.1161/CIRCIMAGING.115.005113.

8. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1–39.e14.

9. Japp AQ, Gulati A, Cook SA, Cowie MR, Prasad SK. The diagnosis and evaluation of dilated cardiomyopathy. J Am Coll Cardiol. 2016. doi:https://10.1016/j.jacc.2016.03.590.

10. Delling FN, Rong J, Larson MG, Lehman B, Fuller D, Oyspiuk E, et al. Evolution of mitral valve prolapse. Circulation. 2016;133(17):1688–95.

11. Kramer CM, Barkhausen J, Flam SD, Kim RJ, Nagel E. Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized Protocols. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson. 2008;10(1):35.

12. Schultz-Menger J, Bluemke DA, Bremricht J, Flam SD, Fogel MA, Fiendrich MG, et al. Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing. J Cardiovasc Magn Reson. 2013;15(1):35. doi:https://10.1186/1532-429X-15-35.

13. Puntmann VO, Gebker R, Duckett S, Mireles J, Schnackenburg B, Graefe M, et al. Left ventricular chamber dimensions and wall thickness by cardiovascular magnetic resonance: comparison with transthoracic echocardiography. 2012. https://academic.oup.com/ehjcmaging/article/14/3/240/2947837.

14. Zia M, Valenti V, Cheston C, Criscito M, Uretsky S, Wolff S. Relation of mitral valve prolapse to basal left ventricular hypertrophy as determined by cardiac magnetic resonance imaging. Am J Cardiol. 2012. doi:https://10.1016/j.amjcard.2011.12.029.

15. Hudsmith LE, Petersen SE, Francis JM, Robson MD, Neubauer S. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson. 2005;7(5):775–82.

16. Gelfand EV, Hughes S, Hauser TH, Yeon SB, Goepfert L, Kissinger KV, et al. Severity of mitral and aortic regurgitation as assessed by cardiovascular magnetic resonance: optimizing correlation with Doppler echocardiography. J Cardiovasc Magn Reson. 2006;8(3):503–7.

17. Huthsmith LE, Petersen SE, Francis JM, Robson MD, Neubauer S. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson. 2005;7(5):775–82.

18. Cerqueira MD. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the cardiac imaging committee of the council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105(4):539–42. doi:https://10.1161/01.HCJ.0000015676.73088.6e.

19. Fleiss JL. The design and analysis of clinical experiments. Hoboken: Wiley; 1990. p. 432.

20. Holm S. A Simple Sequentially Rejective Multiple Test Procedure. In: Scandinavian Journal of Statistics, Vol 2 [Internet]. 1979. p. 65–70. https://www.jstor.org/stable/4615733.

21. Yiginer O, Kesen N, Ozmen N, Tokatli A, Kardesoglu E, Islik Z, et al. Classic mitral valve prolapse causes enlargement in left ventricle even in the absence of significant mitral regurgitation. Echocardiography. 2012;29(2):123–9.

22. Alpendurada F, Wong J, Kiotsekouglo A, Banya W, Child A, Prasad SK, et al. Evidence for Marfan cardiomyopathy. Eur J Heart Fail. 2010;12(10):1085–91.

23. Maron BJ, Sherrid MV, Haas TS, Lindberg J, Kittern C, Lesser JR. Novel hypertrophic cardiomyopathy phenotype: segmental hypertrophy isolated to the posterobasal left ventricular free wall. AJC. 2010;106:750–2.

24. Basso C, Perazzolo Maria M, Rizzo S, De Lazzari M, Giorgi B, Cipriani A, et al. Anhysthmic mitral valve prolapse and sudden cardiac death. Circulation. 2015;132(7):556–66.

25. Kitkungvan D, Nabi F, Kim RJ, Bonow RO, Khan MA, Xu J, et al. Myocardial fibrosis in patients with primary mitral regurgitation with and without prolapse. J Am Coll Cardiol. 2018;72(8):823–34.

26. Edwards NC, Moody WE, Yuan M, Weale P, Neal D, Townend JN, et al. Quantification of left ventricular interstitial fibrosis in asymptomatic chronic primary degenerative mitral regurgitation. Circ Cardiovasc Imaging. 2014;7(6):946–53. doi:https://10.1161/CIRCIMAGING.114.002397.

27. Fukuda S, Song JK, Mahara K, Kuwaki H, Jang JY, Takeuchi M, et al. Basal left ventricular dilatation and reduced contraction in patients with mitral valve prolapse can be secondary to annular dilatation: preoperative and postoperative speckle-tracking echocardiographic study on left ventricle and mitral valve annulus int. Circ Cardiovasc Imaging. 2016. doi:https://10.1161/CIRCIMAGING.115.005113.

28. Zito C, Carerj S, Toddaro MC, Cusma-Piccionne M, Caprino A, Di Bella G, et al. Myocardial deformation and rotational profiles in mitral valve prolapse. Am J Cardiol. 2013;112(7):984–90.

29. Huttin O, Pierre S, Venner C, Voulot D, Sellal JM, Allot E, et al. Interactions between mitral valve and left ventricle: assessed by 2D speckle tracking in patients with mitral valve prolapse: One more piece to the puzzle. Eur Heart J Cardiovasc Imaging. 2017;18(3):323–31.

30. Sanfilippo AJ, Harrigan P, Popovic AD, Weyman AE, Levine RA. Papillary muscle traction in mitral valve prolapse: quantitation by two-dimensional echocardiography. J Am Coll Cardiol. 1992;19(3):564–71.

31. Lee TM, Su SF, Huang TY, Chen MF, Liau CS, Lee YT. Excessive papillary muscle traction and dilated mitral annulus in mitral valve prolapse without mitral regurgitation. Am J Cardiol. 1996;78(4):482–5.

32. Han Y, Peters DC, Kissingar K, Goddu B, Yeon SB, Manning WJ, et al. Evaluation of Papillary Muscle Function Using Cardiovascular Magnetic Resonance Imaging in Mitral Valve Prolapse. 2010[cited 2018 Jul 31]; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992955/pdf/nihms-217445.pdf.

33. Silbiger JI. Anatomy, mechanics, and pathophysiology of the mitral annulus. Am Heart J. 2012;164(2):163–76.

34. Greval J, Suri R, Mankad S, Tanaka A, Mahoney DW, Schaff HV, et al. Mitral annular dynamics in myxomatous valve disease. Circulation. 2010;121(12):1423–31.

35. Delling FN, Kang LL, Yeon SB, Kissinger KV, Goddu B, Manning WJ, et al. CMR predictors of mitral regurgitation in mitral valve prolapse. JACC Cardiovascular Imaging. 2010;3(10):1037–45. doi:https://10.1016/j.jcmg.2010.06.016.

36. Bharati S, Gianston AS, Liebson PR, Loeb HS, Rosen KM, Lev M. The conduction system in mitral valve prolapse syndrome with sudden death. Am Heart J. 1981;101(5):667–70.

37. Newcomb AE, David TE, Lad VS, Bobiarsi J, Armstrong S, Maganti M. Mitral valve repair for advanced myxomatous degeneration with posterior displacement of the mitral annulus. J Thorac Cardiovasc Surg. 2008;136(6):1503–9.

38. Bui AH, Roujol S, Foppa M. Diffuse myocardial fibrosis in patients with mitral valve prolapse and ventricular arrhythmia. Heart. 2017;103:204–9.

39. Delling FN, Kang LL, Yeon SB, Kissinger KV, Goddu B, Manning WJ, et al. Systematic quantification of histologic ventricular fibrosis in isolated mitral valve prolapse and sudden cardiac death. Heart Rhythm. 2021;18(4):570–6.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.